NeoTract, Inc., a medical device company focused on addressing unmet needs in urology, today announced that the company’s UroLift® System received the Phoenix 2016 Most Promising New Product Award at the 23rd Annual Phoenix Conference in Laguna Beach, Calif. The UroLift System was recognized for its novel and much less invasive approach for alleviating symptoms caused by benign prostatic hyperplasia (BPH), also known as an enlarged prostate.
“It is very gratifying to be recognized by the Phoenix Conference organizers and conference attendees, leaders who have developed many breakthroughs that have revolutionized the treatment of a wide variety of conditions,” said Dave Amerson, President and CEO of NeoTract. “UroLift’s selection as the most promising new product from an impressive field of innovations is exciting. We are pleased that our peers recognize the system’s benefits for physicians and for the millions of men who suffer from BPH.”
“The original vision for the UroLift device was to develop an innovative solution for BPH that involved no cutting, heating or removal of tissue, in a simple and intuitive procedure,” said Ted Lamson, Ph.D., founder and Chief Technical Officer of NeoTract. “Bringing the device from concept to fruition has been incredibly rewarding, and is the result of commitment and dedication of the NeoTract team and many collaborative physicians who share our vision for new, better solutions for BPH.”
The Phoenix Awards are presented for outstanding achievement in the medical device and diagnostic industry to individuals and companies selected by industry CEOs. Past recipients of the Most Promising New Product Award include Johnson and Johnson (cardiac stent, drug eluting stent), Guidant (implantable defibrillator), St. Jude Medical (Nanostim), Acclarent (balloon sinuplasty), Neuronetics (NeuroStar TMS Therapy System), CardioMEMS (wireless heart failure management system), and Concentric Medical (clot removal device for stroke).
The UroLift System is a first-line treatment that gets men off BPH medications and allows them to avoid major surgery, while preserving sexual function. Long-term clinical data from the LIFT randomized study published in Urologic Clinics of North America showed that, after four years, patients treated with the UroLift device continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief.1 A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift device compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.2
Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life. Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).
About the Phoenix Conference
Phoenix: The Medical Device and Diagnostic Conference for Chief Executive Officers began in 1994. The conference was developed to provide CEOs in the Medical Device and Diagnostic Industries with an opportunity to meet with peers and explore issues critical to the success of their companies and industries.
About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.UroLift.com.
About NeoTract
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
# # #
Media Contact:
Nicole Osmer
650.454.0505
nicole@nicoleosmer.com
1 Roehrborn Urology Clinics 2016
2 Sonksen et al J Urology 2016
MAC00353-01 Rev A
